Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of leriglitazone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback